Corbus CRB-913 reports 5% mean weight loss in obesity trial
Corbus Pharmaceuticals said its CRB-913 showed dose-dependent weight loss in obese adults, including a 5% mean loss at 60 mg, alongside a favorable safety/tolerability profile. Phase 2 studies are planned for 2027.
Story updates
11:09:01 AM UTC
SquawkNews
CRB-701 demonstrated strong efficacy and a favorable safety profile in 2L OPSCC and cervical cancer, with registrational studies and regulatory filings planned. CRB-913 achieved competitive weight loss and tolerability in Phase 1b obesity trials, supporting advancement to Phase 2.Original document…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.